Destination

2025-03-13

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.

Read more...

[...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination

2025-04-02

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 230.81

Destination

2025-06-03

Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]

Match Score: 225.96

Destination

2025-03-18

Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]

Match Score: 170.84

Destination

2025-04-29

Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 160.91

Destination

2025-01-03

The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 124.30

Destination

2025-05-30

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 88.07

Destination

2025-04-22

Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma

With threats of tariffs hanging over the pharmaceutical industry, Switzerland’s Roche announced on Tuesday that it will invest $50 billion in the United States over the next five years, expanding it [...]

Match Score: 77.59

Destination

2025-05-12

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 77.49

thenextweb

2025-01-10

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 66.54